| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AK4 |
| Uniprot No | P27144 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-223aa |
| 氨基酸序列 | MASKLLRAVILGPPGSGKGTVCQRIAQNFGLQHLSSGHFLRENIKASTEVGEMAKQYIEKSLLVPDHVITRLMMSELENRRGQHWLLDGFPRTLGQAEALDKICEVDLVISLNIPFETLKDRLSRRWIHPPSGRVYNLDFNPPHVHGIDDVTGEPLVQQEDDKPEAVAARLRQYKDVAKPVIELYKSRGVLHQFSGTETNKIWPYVYTLFSNKITPIQSKEAY |
| 预测分子量 | 27.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于AK4重组蛋白的代表性文献摘要(注：文献标题与作者为虚拟示例，实际文献需通过学术数据库检索验证)：
---
1. **文献名称**：*"Recombinant AK4 protein enhances cellular resistance to oxidative stress via AMPK signaling pathway"*
**作者**：Chen L, et al.
**摘要**：研究通过大肠杆菌表达系统成功制备重组人AK4蛋白，并发现其通过激活AMPK通路显著提高细胞对氧化应激的耐受性，提示AK4在代谢调控中的潜在治疗价值。
---
2. **文献名称**：*"Structural and functional characterization of AK4 recombinant protein in mitochondrial energy metabolism"*
**作者**：Wang Y, et al.
**摘要**：利用X射线晶体学解析重组AK4蛋白的三维结构，结合体外酶活实验证实其在线粒体ATP/ADP转换中的催化作用，为靶向AK4的药物设计提供结构基础。
---
3. **文献名称**：*"AK4 recombinant protein suppresses tumor growth by modulating hypoxia-inducible factor 1α (HIF-1α) in colorectal cancer"*
**作者**：Kim S, et al.
**摘要**：通过哺乳动物细胞表达系统获得高纯度AK4重组蛋白，证明其通过抑制HIF-1α信号通路降低结直肠癌细胞在缺氧环境下的存活率，揭示其抗肿瘤机制。
---
**建议**：实际文献可通过PubMed或Google Scholar检索关键词 *"recombinant AK4 protein"* 或 *"adenylate kinase 4 expression"* 获取，重点关注蛋白功能、疾病关联及重组表达技术相关研究。
Adenylate kinase 4 (AK4) is a member of the adenylate kinase family, a group of enzymes critical for maintaining cellular energy homeostasis by catalyzing the reversible transfer of phosphate groups between nucleotides. Unlike other isoforms (e.g., AK1. AK2. AK3), AK4 is localized primarily in the mitochondria and cytosol, playing a role in balancing ATP/AMP levels under metabolic or oxidative stress. Its unique structural features, including a conserved catalytic core and distinct substrate-binding regions, enable functional versatility beyond energy metabolism, such as modulating cellular responses to hypoxia and reactive oxygen species (ROS).
Recombinant AK4 protein is produced using biotechnological platforms like *E. coli* or mammalian expression systems, followed by purification via affinity chromatography. This engineered protein retains enzymatic activity and structural integrity, making it a valuable tool for studying AK4’s biological roles. Research has linked AK4 dysregulation to pathologies including cancer, neurodegenerative diseases, and metabolic disorders. For instance, AK4 overexpression in tumors correlates with chemoresistance and poor prognosis, likely due to its involvement in mitochondrial apoptosis pathways and stress adaptation.
In drug discovery, recombinant AK4 facilitates high-throughput screening for inhibitors or activators targeting its enzymatic or regulatory domains. Structural studies using recombinant protein have revealed interactions with substrates like AMP/ATP and potential allosteric modulators. Additionally, AK4’s role in metabolic reprogramming and oxidative stress response positions it as a biomarker for disease diagnosis or a therapeutic target. Ongoing research aims to elucidate its non-catalytic functions, including crosstalk with signaling pathways like HIF-1α and mTOR, highlighting its multifaceted impact on cell survival and adaptation.
×
